ギリアドサイエンシズ：製薬企業分析レポート

Abstract

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercialises ethical drugs. This report provides a full review of the company’s activities together with sales forecasts for key products to 2011.

Gilead Sciences, incorporated on 22nd June 1987, and headquartered in Foster City, CA, is a biopharmaceutical company that discovers, develops and commercialises ethical drugs. Traditionally, the company has predominantly developed treatments for life-threatening infectious diseases, however, in 2006, Gilead expanded its research, development and commercial focus to include respiratory and cardiopulmonary disease through the acquisition of two pharmaceutical companies.

Gilead attributes its recent success and growing revenue to strong global organisation and infrastructure. The company intends to continue investment in improving this infrastructure to facilitate ongoing growth in short- to medium-term. In 2006, Gilead undertook a strategic realignment of its international commericial organisation to better build, manage and expand its presence in new and existing markets. Gilead is analysing and restructuring the way it distributes products as well as enhancing its manufacturing capabilities in order to cope with growing demand for its products. The acquisition of Raylo Chemicals was a core component of this strategy.

The cost of funding corporate development opportunities (including three significant acquisitions in 2006), building infrastructure and meeting daily operating needs continued to be an area of management focus in 2006. During this fiscal period, Gilead achieved record sales, however, increased costs resulted in significant losses in operating and net income. For 2007, Gilead hopes to maintain sales growth whilst achieving a greater balance with corporate spending. The company also recognises its strong reliance on its corporate partners, and hopes to maintain strong working relationships especially with Roche, Bristol-Myers Squibb, Merck & Co and GlaxoSmithKline.

In addition to Gilead’s various collaborations with other companies and research institutions, the company is seeking to add to its product portfolio through its own internal and clinical development programmes. The acquisitions of Myogen and Corus Pharma have significantly expanded the scope of Gilead’s research efforts.

Table of Contents

Latest Results

EXECUTIVE SUMMARY

• Introduction
• Current Financial Position
  • Company Performance
  • Business Segment Performance
  • Geographic Segment Performance
• Company Strategy
  • Mergers, Acquisitions and Divestitures
  • Key Agreements
  • Employees
• Product Performance Forecasts
• Pipeline Analysis
• Conclusions/Outlook
• Other Factors Affecting the Bottom Line

THERAPEUTIC AREA FOCUS

R&D PIPELINE

ANTI-VIRAL

• Marketed Products
  • HIV
    • Atripla
    • Truvada
    • Viread
    • Others
  • Hepatitis
    • Hepsera
• R&D Projects
  • HIV
    • GS 9137
  • Hepatitis
  • Discontinued R&D Projects
• Growth Forecast
  • HIV
  • Hepatitis

OTHER AREAS

• Marketed Products
  • AmBisome
  • Others
• R&D Projects
  • Ambrisentan
  • Aztreonam lysine
  • Darusentan
• GROWTH FORECAST

APPENDIX 1 - FINANCIAL PERFORMANCE

• Full Year Results 2006

APPENDIX 2 - KEY CORPORATE EVENTS

APPENDIX 3 - KEY AGREEMENTS

• 4AZA Bioscience
• Achillion Pharmaceuticals
• Anadys Pharmaceuticals
• Aspen Pharmacare
• Astellas Pharma
• Bristol-Myers Squibb
• Chimerix
• Dainippon Sumitomo Pharma
• Diatos
• Emory University/Royalty Pharma
• Genelabs Technologies
• GlaxoSmithKline
• International Partnership for Microbicides /CONRAD
• Japan Tobacco
• Merck & Co
• Novartis
• Roche

APPENDIX 4 - INFRASTRUCTURE

• Research and Development Facilities
• Manufacturing Facilities

APPENDIX 5 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINT VENTURES

• Subsidiaries
• Joint Ventures

APPENDIX 6 - PRODUCT INDEX

Index of Tables

• Principal Operating Results
• R&D Expenditure
• Sales By Destination
• Major Products, Therapeutic Areas and Sales
• Major HIV Products, 2006
• Major Hepatitis Products, 2006
• Major Other Area Products, 2006

Index of Charts

• R&D Expenditure, 2006
• Sales By Destination
• Sales of Top Five Products (2004A-2011E)
• Top Selling Products, 2006
• Atripla Sales (2000A-2010E)
• Truvada Sales (2001A-2011E)
• Viread Sales (2001A-2011E)
• Hepsera Sales (2001A-2010E)
• GS 9137 Sales (2001A-2011E)
• HIV Product Portfolio Forecast (2006A-2011E)
• AmBisome Sales (2001A-2011E)
• Sales, Costs and Operating Income
• Profitability and Research Ratios
• R&D Expenditure and Capital Expenditure
• Current Assets, Liabilities and Ratio
• Assets, Cash and Liquidity
• Employees and Productivity